Home / Peptides / Peptides for Libido

Do Peptides Increase Libido? PT-141 (Bremelanotide) Evidence for Men and Women

PT-141 (bremelanotide) is the only FDA-approved peptide for low sexual desire: in two phase 3 trials of 1,267 premenopausal women it raised desire and lowered distress, and in men it produced erections even after an inadequate response to sildenafil, at the cost of nausea in about 40%.

Written by

Mahadev Mukherjee

B.Sc. (Hons) Chemistry, MBA Pharma Mgmt (Pursuing) · Scientific Content Writer, Strong Health

Medically reviewed by

Dr. Angel Rivera, M.D.

M.D., Staff Psychiatrist · Medical Reviewer, Strong Health

Published: February 1, 2026 Updated: October 25, 2026 · Editorial Standards

10 min read

Key takeaways

PT-141 (bremelanotide, Vyleesi) is the only FDA-approved peptide for low sexual desire, approved in 2019 for premenopausal women with HSDD.^[1]
In two phase 3 trials of 1,267 women, bremelanotide significantly increased desire and reduced distress versus placebo over 24 weeks.^[1]
In men, PT-141 produced statistically significant erections even in patients with an inadequate response to sildenafil (Viagra).^[3]
It works in the brain on melanocortin-4 receptors, not on blood flow, so it addresses desire rather than erection mechanics.^[4]
Nausea affects about 40% of users, flushing 20% and headache 11%; each dose transiently raises blood pressure, so uncontrolled hypertension is a contraindication.^[1]

Table of Contents

What is PT-141 (bremelanotide)?

PT-141, known by its pharmaceutical name bremelanotide (brand name Vyleesi), is a synthetic melanocortin peptide that acts on MC4 receptors in the brain to increase sexual desire, unlike erectile dysfunction drugs that act on blood flow.^[4] Most treatments for sexual dysfunction focus on plumbing: blood flow, erection mechanics. PT-141 does something fundamentally different.

That distinction matters more than most people realize. Many patients with low libido have perfectly adequate vascular function. Their bodies can respond to stimulation just fine. The problem is upstream: the desire signal from the brain has gone quiet. This is especially common in people dealing with hormonal shifts, chronic stress, medication side effects, or the gradual decline in sexual interest that often comes with age.

PT-141 grew out of research on melanocortin peptides, a family of signaling molecules involved in energy regulation, inflammation, and sexual function. When researchers discovered that activating melanocortin receptors could stimulate sexual desire, it launched over two decades of clinical development, ultimately leading to FDA approval for a specific indication in 2019.

How does PT-141 work?

PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus, a brain region that regulates sexual behavior, appetite, and energy balance. This mechanism is fundamentally different from all other available treatments for sexual dysfunction:

•Central nervous system action: PT-141 crosses into the brain and activates desire pathways directly, rather than working on peripheral blood vessels
•Melanocortin receptor activation: By binding to MC4R receptors, PT-141 triggers downstream signaling cascades that increase sexual arousal and desire
•Dopaminergic involvement: PT-141's mechanism involves modulation of dopamine pathways, which are central to motivation and reward, including sexual motivation
•Gender-independent mechanism: The melanocortin system governs sexual desire in both men and women, which is why PT-141 has demonstrated efficacy across genders

PT-141 is the only FDA-approved treatment that addresses sexual desire through central nervous system pathways. All other approved treatments for sexual dysfunction work peripherally (PDE5 inhibitors) or hormonally (testosterone replacement).^[1]

Is PT-141 FDA-approved?

Yes, for one indication: in June 2019 the FDA approved bremelanotide (brand name Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on two phase 3 RECONNECT trials that randomized 1,267 women.^[1]

Key Approval Details

•Approved indication: Hypoactive sexual desire disorder (HSDD) in premenopausal women
•Administration: Subcutaneous injection (autoinjector) at least 45 minutes before anticipated sexual activity
•Dosage: 1.75 mg per injection, no more than one dose per 24 hours, maximum 8 doses per month
•Not approved for: Male sexual dysfunction (though off-label physician use occurs)
•Prescription required: Available only through healthcare providers

For male patients, PT-141 is used off-label under physician supervision. While not FDA-approved for male sexual dysfunction, a placebo-controlled crossover study demonstrated statistically significant erectile responses in men with erectile dysfunction who had an inadequate response to sildenafil.^[3]

How does PT-141 compare with Viagra and Cialis?

Seeing PT-141 side by side with conventional ED medications makes the differences clear, and helps determine which approach makes sense for a given patient:

PT-141 compared with PDE5 inhibitors
Factor	PT-141 (bremelanotide)	PDE5 inhibitors (sildenafil, tadalafil)
Mechanism	Central nervous system (brain melanocortin receptors)	Peripheral (penile blood flow)
Primary effect	Increases desire and arousal	Improves erectile function
Works for women?	Yes (FDA-approved for premenopausal HSDD)^[1]	No approved indication
Blood pressure	Transient rise of about 6 mmHg systolic and slower heart rate after each dose; contraindicated in uncontrolled hypertension	Can cause significant drops, especially with nitrates
Nitrate interaction	No listed interaction	Contraindicated: dangerous hypotension
Onset	About 45 minutes before activity	15–60 minutes
Duration	Several hours	4–36 hours depending on drug
Administration	Subcutaneous autoinjector	Oral tablet
Most common side effect	Nausea (about 40%)^[1]	Headache, flushing

A key advantage of PT-141 is its safety profile for patients taking nitrate medications for heart conditions. PDE5 inhibitors are strictly contraindicated with nitrates due to the risk of dangerous blood pressure drops. PT-141, working through a completely different pathway, has no listed nitrate interaction, though it carries its own blood-pressure warning.

For patients interested in a broader approach to sexual health, our clinic also offers a full range of physician-supervised peptide protocols that may address multiple health concerns simultaneously.

Can peptides treat erectile dysfunction?

Peptides can treat the desire-driven component of erectile dysfunction, not the vascular one: PT-141 produced statistically significant erections in men who had an inadequate response to sildenafil, in a placebo-controlled crossover study.^[3] Erectile dysfunction is not one condition. It has both a vascular component (blood flow into erectile tissue) and a neurological, desire-driven component, and which one is driving the problem determines whether a peptide has a role.

PDE5 inhibitors like Viagra and Cialis address the vascular, mechanical side. PT-141 works on the other side of the equation: the central nervous system pathways that govern desire and arousal. That is why it can help a subset of men that PDE5 inhibitors do not: in a placebo-controlled crossover study, PT-141 at 4 mg and 6 mg produced statistically significant erectile responses in men whose erections were adequate half the time or less on 100 mg of sildenafil (Viagra), consistent with a neurological rather than purely vascular cause.^[3]

Peptides are not a universal cure for erectile dysfunction. When ED is primarily vascular, PDE5 inhibitors or treating the underlying cause remain first-line. And because new or persistent ED can be an early warning sign of cardiovascular disease, diabetes, or low testosterone, it should always be medically evaluated rather than self-treated.

Where ED is tied to overstimulation and dopamine desensitization rather than a physical problem, the fix is behavioral rather than pharmacological. See our guide to recovering from porn-induced ED. Our physicians evaluate the full picture (hormones, vascular health, medications, and psychology) before recommending PT-141, a PDE5 inhibitor, testosterone optimization, or a combination.

Does PT-141 work for low libido in women?

Yes: PT-141 is FDA-approved for hypoactive sexual desire disorder in premenopausal women, and in the RECONNECT trials it significantly increased desire and reduced distress compared with placebo.^[1] Low libido in women is one of the few areas of sexual health with an FDA-approved peptide treatment, and HSDD means persistently low sexual desire that causes distress and is not explained by another medical or relationship issue.

Because the melanocortin system governs sexual desire in both sexes, PT-141 works the same way in women as in men: it acts on the brain's desire pathways rather than on blood flow or lubrication. It is dosed on demand ahead of anticipated activity, not taken daily. In the Phase 3 RECONNECT trials of more than 1,200 women, PT-141 produced a statistically significant increase in desire and a meaningful reduction in the distress associated with low desire.^[1]

As with men, a low sex drive in women can also stem from hormonal shifts (including perimenopause and postpartum changes), thyroid dysfunction, medication side effects, or chronic stress. Our physicians evaluate these contributing factors before prescribing, so treatment addresses the actual cause rather than only the symptom.

What does the clinical evidence show?

PT-141 has one of the strongest evidence bases of any peptide therapy: two phase 3 randomized trials in women, placebo-controlled crossover studies in men, and dose-finding studies that set the 1.75 mg dose.^[1][2][3]

“Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.”

Kingsberg SA, et al., Obstetrics & Gynecology, 2019 (RECONNECT phase 3 trials) — PubMed

Key clinical studies of PT-141 (bremelanotide)
Study	Population	Design	Key result
RECONNECT 301 and 302^[1]	1,267 premenopausal women with HSDD	Two 24-week randomized, placebo-controlled phase 3 trials	Desire score up 0.30 and 0.42 vs placebo (P<.001); distress reduced; nausea 40%
Clayton 2016^[2]	327 premenopausal women with sexual dysfunction	Randomized dose-finding trial	+0.7 vs +0.2 satisfying sexual events per month; FSFI total +3.6 vs +1.9
Rosen 2004^[3]	Healthy men and men with inadequate response to sildenafil	Placebo-controlled crossover, 4 and 6 mg	Statistically significant erectile response at both doses
Diamond 2006^[5]	18 premenopausal women with arousal disorder	Crossover, single 20 mg intranasal dose	More women reported moderate or high desire vs placebo (P = 0.0114)

RECONNECT Trials (Phase 3)

Two randomized, placebo-controlled Phase 3 trials enrolled over 1,200 premenopausal women with HSDD. Key findings included:^[1]

•Statistically significant increase in sexual desire compared to placebo
•Meaningful reduction in distress associated with low sexual desire
•Improvements maintained over 24 weeks of treatment
•Integrated desire score increased 0.35 versus placebo across both studies (P<.001)

Male Efficacy Data

In a placebo-controlled crossover study, men with erectile dysfunction and an inadequate response to sildenafil (Viagra) received placebo, 4 mg or 6 mg of PT-141 with visual sexual stimulation; the erectile response was statistically significant at both doses, suggesting a role for men whose ED has a neurological rather than purely vascular cause.^[3]

Dose-Finding Studies

Earlier dose-finding studies established that the 1.75 mg subcutaneous dose provided the optimal balance of efficacy and tolerability, with higher doses not offering meaningful additional benefit but increasing side effect rates.^[2]

How is PT-141 prescribed at Strong Health?

At Strong Health, PT-141 therapy follows a structured clinical protocol:

•Thorough evaluation: Medical history, hormonal assessment (testosterone, estradiol, thyroid), and review of current medications to identify contributing factors
•Baseline assessment: Sexual health questionnaires to establish measurable treatment goals
•Prescription and training: If appropriate, patients receive a prescription and training on self-administered subcutaneous injection
•Follow-up: Regular check-ins to assess response, adjust dosing, and monitor for side effects
•Integrated approach: When indicated, PT-141 may be combined with hormonal optimization, lifestyle modifications, or other therapies

PT-141 is administered as needed, approximately 45 minutes before anticipated sexual activity. It is not a daily medication, which many patients prefer for its on-demand convenience.

What are the side effects of PT-141?

The most common side effects of PT-141 in the phase 3 trials were nausea (about 40%), flushing (20%) and headache (11%), mostly mild to moderate.^[1] The most commonly reported side effects include:

•Nausea: The most common side effect (approximately 40% of patients), usually mild and decreasing with subsequent doses
•Flushing: Transient facial flushing reported in approximately 20% of patients
•Headache: Reported in approximately 11% of patients
•Injection site reactions: Mild redness or discomfort at the injection site
•Temporary skin darkening: Focal hyperpigmentation has been reported, particularly around the face and gums, which usually resolves after discontinuation

The Vyleesi label warns of a transient increase in blood pressure and decrease in heart rate after each dose. It is contraindicated in uncontrolled hypertension or known cardiovascular disease, and blood pressure should be well controlled before starting and checked after early doses.

Who benefits most from PT-141?

PT-141 may be most appropriate for:

•Women with HSDD: The FDA-approved indication, supported by Phase 3 clinical trial data
•Men whose ED has a desire or arousal component: PT-141 produced erections in men with an inadequate response to sildenafil in a controlled study
•PT-141 has no listed nitrate interaction, an option to discuss when PDE5 inhibitors are contraindicated, subject to its own blood-pressure warning
•Patients with desire-specific issues: Those who can achieve physical arousal but lack the motivational/desire component
•Patients seeking on-demand therapy: PT-141's as-needed dosing avoids the need for daily medication

For patients whose low libido is related to hormonal imbalance, testosterone optimization may be a more appropriate first-line treatment. Our physicians evaluate the full clinical picture to recommend the most effective approach. When low libido stems from hormonal imbalance, explore testosterone therapy in Miami or our guide to recovering from porn-induced ED.

Frequently Asked Questions

Which peptides help with sex drive?

PT-141 (bremelanotide) is the peptide most directly used for sex drive because it acts on melanocortin receptors in the brain to increase desire itself, in both men and women. Where low sex drive is driven by hormonal decline, peptides that support the body's own hormonal signaling, or testosterone optimization, may be more appropriate first. Because the causes of low libido differ from person to person, the right peptide is determined by a physician evaluation, not a one-size-fits-all stack.

Can peptides treat erectile dysfunction?

PT-141 can help a specific type of erectile dysfunction: the neurological, desire-driven kind. In studies, roughly one-third of men who did not respond to sildenafil (Viagra) achieved erections with PT-141. It is not a universal ED cure: erectile dysfunction that is primarily vascular is usually better addressed with PDE5 inhibitors or by treating the underlying cause. Because ED can be an early sign of cardiovascular disease, any new or persistent ED should be medically evaluated.

Are there peptides for low libido in women?

Yes. PT-141, branded as Vyleesi, is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, and it is one of the few approved treatments for low sexual desire in women. It targets the desire pathway in the brain rather than blood flow or lubrication, and is dosed on demand under physician supervision after evaluation for hormonal and other contributing causes.

Can peptides improve sexual performance?

It depends on what you mean by performance. PT-141 improves desire and arousal by acting in the brain; it does not primarily improve the mechanics of erection the way PDE5 inhibitors (Viagra, Cialis) do. For many patients the limiting factor is desire rather than blood flow, which is where PT-141 fits. A physician can determine whether desire, vascular function, hormones, or a combination is driving the concern.

How is PT-141 different from Viagra or Cialis?

PT-141 works through the central nervous system by activating melanocortin receptors in the brain, addressing the neurological component of sexual desire. Viagra and Cialis work peripherally by increasing blood flow to erectile tissue. PT-141 addresses desire (libido), while PDE5 inhibitors primarily address the mechanical aspect of erection.

Can women use PT-141?

Yes. Women are the only group PT-141 is actually approved for: Vyleesi is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder, meaning low desire that causes distress and is not explained by a medical condition, relationship problem or medication. It is taken as an autoinjector dose at least 45 minutes before anticipated sex, no more than once in 24 hours and eight times a month. Use in postmenopausal women is off-label.

How quickly does PT-141 work?

PT-141 is dosed about 45 minutes before anticipated sexual activity, which is when the label says to inject it, and its effect on desire and arousal builds over the following hours rather than in minutes. In the phase 3 trials women used it as needed over 24 weeks and the benefit on desire and distress was measured across that period, so judge it over several uses, not one. Nausea, if it occurs, tends to appear within the first couple of hours.

Is PT-141 safe to use with blood pressure medication?

Only with a physician’s review. Each dose of PT-141 causes a transient rise in blood pressure (about 6 mmHg systolic) and a small drop in heart rate that resolves within about 12 hours, and the label contraindicates it in uncontrolled hypertension or known cardiovascular disease. Well-controlled hypertension on medication is not an automatic exclusion, but your physician should confirm control before prescribing and check blood pressure after early doses. Unlike PDE5 inhibitors, PT-141 has no listed interaction with nitrates.

How often can PT-141 be used?

The approved schedule is no more than one dose in 24 hours and no more than eight doses per month, injected subcutaneously about 45 minutes before anticipated activity. Those limits come from the phase 3 trials and the blood-pressure effect of each dose. Men using PT-141 off-label follow similar limits under physician supervision. If you find you need it far more often, that is a signal to revisit the underlying causes of low desire rather than to increase the dose.

Does PT-141 require a prescription?

Yes. Bremelanotide (Vyleesi) is a prescription-only drug in the United States, approved for premenopausal women with hypoactive sexual desire disorder, and any use in men is off-label and still requires a physician. Products sold online as “PT-141” without a prescription come from unregulated sources with no guarantee of identity, purity, sterility or dose, which matters for a compound that raises blood pressure. A legitimate prescription also comes with a hormone and medication review that often finds the real cause of low desire.

Can PT-141 be combined with other peptide therapies?

Sometimes, under supervision. PT-141 acts on brain melanocortin receptors and has no known interaction with growth hormone secretagogues or healing peptides, so combinations are mainly a question of whether each one is justified on its own. The more useful combination is with treatment of the underlying cause: testosterone optimization when levels are low, treating depression or medication effects, or a PDE5 inhibitor when ED has a vascular component. Every added compound adds side-effect risk, so your physician should introduce one change at a time.

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided has been reviewed by licensed healthcare professionals but individual results may vary.